Arbutus Biopharma Corp (ABUS)vsAstraZeneca PLC (AZN)
ABUS
Arbutus Biopharma Corp
$4.25
-2.30%
HEALTHCARE · Cap: $884.97M
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 31470% more annual revenue ($60.44B vs $191.44M). ABUS leads profitability with a 84.0% profit margin vs 17.2%. ABUS trades at a lower P/E of 5.4x. AZN earns a higher WallStSmart Score of 64/100 (C+).
ABUS
Buy63
out of 100
Grade: C+
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABUS.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 62 in profit
Keeps 84 of every $100 in revenue as profit
Strong operational efficiency at 94.4%
Revenue surging 10055.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABUS
The strongest argument for ABUS centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 84.0% and operating margin at 94.4%. Revenue growth of 10055.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ABUS
The primary concerns for ABUS are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ABUS profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
ABUS carries more volatility with a beta of 0.62 — expect wider price swings.
ABUS is growing revenue faster at 10055.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 63/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arbutus Biopharma Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?